Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Porst

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
Journal of Andrology|July 14, 2012
Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitorsHartmut Porst, Gerald B Brock, Krzysztof Kula, et al.
The Journal of Sexual Medicine|January 21, 2006
Vardenafil improves satisfaction rates, depressive symptomatology, and self-confidence in a broad population of men with erectile dysfunctionDimitrios Hatzichristou, Beatrice Cuzin, Antonio Martin-Morales, et al.
The Journal of Sexual Medicine|January 21, 2006
Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trialFrancesco Montorsi, Harin Padma-Nathan, Jacques Buvat, et al.
The Journal of Sexual Medicine|January 23, 2010
Standards for clinical trials in male sexual dysfunctionsHartmut Porst, Yoram Vardi, Emre Akkus, et al.
European Urology|June 13, 2006
Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trialHartmut Porst, François Giuliano, Sidney Glina, et al.
Mayo Clinic Proceedings|October 11, 2005
Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: a randomized, double-blind, placebo-controlled studyLuc Valiquette, Jay M Young, Ignacio Moncada, et al.
The Journal of Sexual Medicine|April 24, 2010
Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analyses of two phase 3 dapoxetine trialsHartmut Porst, Chris G McMahon, Stanley E Althof, et al.
Urology|October 31, 2006
Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunctionRidwan Shabsigh, Allen D Seftel, Raymond C Rosen, et al.
European Urology|August 30, 2011
Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trialHartmut Porst, Edward D Kim, Adolfo R Casabé, et al.
European Urology|January 26, 2016
Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic HyperplasiaMauro Gacci, Karl-Erik Andersson, Christopher Chapple, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Journal of Andrology|July 14, 2012
Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitorsHartmut Porst, Gerald B Brock, Krzysztof Kula, et al.
The Journal of Sexual Medicine|January 21, 2006
Vardenafil improves satisfaction rates, depressive symptomatology, and self-confidence in a broad population of men with erectile dysfunctionDimitrios Hatzichristou, Beatrice Cuzin, Antonio Martin-Morales, et al.
The Journal of Sexual Medicine|January 21, 2006
Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trialFrancesco Montorsi, Harin Padma-Nathan, Jacques Buvat, et al.
The Journal of Sexual Medicine|January 23, 2010
Standards for clinical trials in male sexual dysfunctionsHartmut Porst, Yoram Vardi, Emre Akkus, et al.
European Urology|June 13, 2006
Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trialHartmut Porst, François Giuliano, Sidney Glina, et al.
Mayo Clinic Proceedings|October 11, 2005
Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: a randomized, double-blind, placebo-controlled studyLuc Valiquette, Jay M Young, Ignacio Moncada, et al.
The Journal of Sexual Medicine|April 24, 2010
Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analyses of two phase 3 dapoxetine trialsHartmut Porst, Chris G McMahon, Stanley E Althof, et al.
Urology|October 31, 2006
Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunctionRidwan Shabsigh, Allen D Seftel, Raymond C Rosen, et al.
European Urology|August 30, 2011
Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trialHartmut Porst, Edward D Kim, Adolfo R Casabé, et al.
European Urology|January 26, 2016
Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic HyperplasiaMauro Gacci, Karl-Erik Andersson, Christopher Chapple, et al.
Pageof 7